Page 3 - Nasdaq Cyth News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) and Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership. Analyst Ratings This is a summary of […]

Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) and Krystal Biotech (NASDAQ:KRYS – Get Rating) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability. Volatility & Risk Cyclo Therapeutics has a beta of -0.41, […]

Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) and Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations. Analyst Ratings This is a summary of recent recommendations […]

Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) and Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership. Analyst Recommendations This is a breakdown of current ratings […]

Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Rating) COO Jeffrey Tate bought 29,941 shares of the stock in a transaction on Thursday, April 20th. The stock was purchased at an average cost of $0.71 per share, for a total transaction of $21,258.11. Following the acquisition, the chief operating officer now directly owns 62,101 shares of the […]